News coverage about Puma Biotechnology (NASDAQ:PBYI) has trended somewhat positive recently, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Puma Biotechnology earned a coverage optimism score of 0.21 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.2386177330034 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the media headlines that may have effected Accern Sentiment’s analysis:

Shares of Puma Biotechnology (NASDAQ:PBYI) remained flat at $$97.15 during trading hours on Friday. The company’s stock had a trading volume of 603,436 shares, compared to its average volume of 941,432. Puma Biotechnology has a 52 week low of $28.35 and a 52 week high of $136.90. The company has a market capitalization of $3,650.00, a PE ratio of -11.86 and a beta of 0.73.

Puma Biotechnology (NASDAQ:PBYI) last announced its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.50) by $0.43. The company had revenue of $6.10 million during the quarter, compared to analysts’ expectations of $3.78 million. During the same quarter last year, the firm posted ($1.11) earnings per share. sell-side analysts forecast that Puma Biotechnology will post -8.19 EPS for the current fiscal year.

A number of equities research analysts recently commented on the stock. Royal Bank of Canada lowered their price target on shares of Puma Biotechnology from $108.00 to $92.00 and set a “sector perform” rating on the stock in a report on Friday, November 10th. They noted that the move was a valuation call. Credit Suisse Group reiterated an “outperform” rating and issued a $136.00 price objective on shares of Puma Biotechnology in a research note on Wednesday, September 27th. BidaskClub upgraded shares of Puma Biotechnology from a “hold” rating to a “buy” rating in a research note on Friday, September 8th. Barclays began coverage on shares of Puma Biotechnology in a research note on Wednesday, September 6th. They issued an “overweight” rating and a $103.00 price objective for the company. Finally, J P Morgan Chase & Co reiterated a “buy” rating and issued a $131.00 price objective on shares of Puma Biotechnology in a research note on Wednesday, October 4th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $130.67.

In other news, insider Charles R. Eyler sold 1,322 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $105.46, for a total transaction of $139,418.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Richard Paul Bryce sold 15,000 shares of the company’s stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $120.00, for a total transaction of $1,800,000.00. Following the transaction, the senior vice president now directly owns 42,239 shares of the company’s stock, valued at $5,068,680. The disclosure for this sale can be found here. Insiders own 21.10% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Puma Biotechnology (PBYI) Receiving Somewhat Favorable Press Coverage, Accern Reports” was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://theolympiareport.com/2017/12/23/puma-biotechnology-pbyi-receiving-somewhat-favorable-press-coverage-accern-reports.html.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Insider Buying and Selling by Quarter for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.